미세 유체 흐름 챔버 지혈 및 혈소판 수혈을 모델링하기 위해 재구성 된 혈액을 사용하여 체외

Executive Industry Relevance

This protocol enables biopharma R&D teams to evaluate platelet transfusion efficacy under physiologically relevant flow conditions, addressing a critical gap in preclinical assessment of blood product quality. By simulating hemostasis in microfluidic chambers using reconstituted blood, the method provides quantitative, real-time readouts of platelet function that support go/no-go decisions in transfusion medicine development. The approach de-risks translational advancement by linking storage variables to functional outcomes, thereby improving predictive confidence in platelet product performance.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Interrogates therapeutic hypotheses regarding platelet function and storage lesion impact on hemostasis.
• Operational Value: Enables functional target validation of platelet concentrates under controlled shear stress and temperature conditions.
• Predictive Value: Supports portfolio triage by correlating platelet concentration, storage duration, and temperature cycling with thrombus growth kinetics.

Screening & Assay Development

• Assay Readiness: Prepares validated biological systems for downstream screening of platelet-modulating compounds or storage interventions.
• Reproducibility: Delivers quantitative surface coverage measurements with low intra-assay variation (8.7% CV), enabling reliable compound evaluation.
• Scalability: Supports multiplexed testing of three identical reconstituted blood samples simultaneously over collagen-coated surfaces.

Translational & Preclinical Research

• Disease Relevance: Models thrombocytopenia treatment scenarios using reconstituted blood to mimic clinical platelet transfusion.
• Translational Continuity: Bridges discovery and preclinical validation by measuring hemostatic function on collagen under hydrodynamic flow.
• Risk-Adjusted Decisions: Informs advancement decisions by quantifying the impact of blood donation, transport, component separation, storage, and pathogen inactivation on platelet function.

Pipeline & Workflow Integration

The method integrates into the discovery continuum from early target validation through preclinical assessment, enabling continuous evaluation of platelet product quality across the processing chain.

• Discovery Biology: Supports hypothesis testing of platelet storage lesions and pathway clarification of hemostasis under flow.
• Screening: Provides assay-ready, reproducible systems for evaluating platelet adhesion and thrombus growth kinetics.
• Analytics: Generates quantitative thrombus growth kinetics via image analysis and linear regression, enabling cross-condition comparison.
• Translational Research: Connects to preclinical continuity by simulating transfusion and measuring functional outcomes in disease-relevant shear conditions.
• Enterprise Reuse: Establishes a reusable capability for assessing platelet product quality across multiple storage variables and processing steps.

Operational & Enterprise Impact

• Scientific Value: Delivers predictive confidence in platelet function by reducing mechanistic ambiguity in storage lesion effects.
• Operational Value: Ensures standardization and reproducibility through controlled perfusion, blocking, and imaging protocols.
• Strategic Value: Improves go/no-go decisions by linking storage duration, temperature, and shear rate to functional platelet outcomes.
• Portfolio Impact: Enables risk-adjusted prioritization of platelet processing optimizations based on empirical hemostasis data.

Implementation Considerations

• Requires expertise in microfluidic handling, blood reconstitution, and real-time microscopy.
• Dependent on automated microscope stage, pump-manifold system, and biocompatible biochips.
• Necessitates cross-team standardization of hematocrit, platelet concentration, and perfusion pressure settings.
• Involves adaptation considerations for varying shear rates, temperature profiles, and surface coatings (e.g., collagen, VWF, fibrinogen).
• Practical limitations include the need for air bubble-free channel filling and precise Z-focus maintenance during perfusion.

Biopharma FAQs